Immunitybio Inc
NASDAQ:IBRX
Immunitybio Inc
Revenue
Immunitybio Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Immunitybio Inc
NASDAQ:IBRX
|
Revenue
$622k
|
CAGR 3-Years
1%
|
CAGR 5-Years
66%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Immunitybio Inc
Revenue Breakdown
Breakdown by Geography
Immunitybio Inc
Total Revenue:
622k
USD
|
Europe:
591k
USD
|
United States:
31k
USD
|
Breakdown by Segments
Immunitybio Inc
See Also
What is Immunitybio Inc's Revenue?
Revenue
622k
USD
Based on the financial report for Dec 31, 2023, Immunitybio Inc's Revenue amounts to 622k USD.
What is Immunitybio Inc's Revenue growth rate?
Revenue CAGR 5Y
66%
Over the last year, the Revenue growth was 159%. The average annual Revenue growth rates for Immunitybio Inc have been 1% over the past three years , 66% over the past five years .